Jim Cramer Says: “J&J Deserves to Be Going Higher, But Not at This Speed, Not at This Pace”

Group 1 - Johnson & Johnson (NYSE: JNJ) is viewed positively by money managers as a resilient stock during economic slowdowns, with essential products like toothpaste and medicine that consumers will purchase regardless of economic conditions [1] - The recent stock performance of JNJ suggests strong investor interest, although the pace of its rally may be influenced by a broader market sentiment favoring defensive stocks amid economic uncertainty [1] - JNJ is being favored over other pharmaceutical stocks like Eli Lilly, which has a higher price-to-earnings multiple, making it appear riskier to investors in the current climate [1] Group 2 - Johnson & Johnson develops and sells a wide range of healthcare products, including pharmaceuticals and medical technologies, with a focus on areas such as immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2] - The company also provides various medical devices and solutions, including surgical systems, orthopedic solutions, cardiovascular devices, and vision care products [2]